Fig. 4

UBE2S enhances Olaparib resistance in ovarian cancer cells. A2780 and SKOV3 cells transfected with PCMV and PCMV-UBE2S (UBE2S) were treated with Olaparib (A2780, 15 μM; SKOV3, 30 μM) for 48 h and 72 h. A The CCK8 assay was performed to detect cell viability. B The protein level of PARP, cleaved caspase 3, and β-actin were detected by western blot. C and D Quantification of relative protein levels in (B). E Clonogenic assay was performed to determine the colony formation efficiency of A2780 and SKOV3 cells. F Quantification of the number of clones in (E). A2780 and SKOV3 cells transfected with PLKO.1 and UBE2S shRNA2 (sh-2) were treated with Olaparib (A2780, 15 μM; SKOV3, 30 μM) for 48 h and 72 h. G The CCK8 assay was performed to detect cell viability. H The protein level of PARP, cleaved caspase 3, and β-actin were detected by western blot. I and J Quantification of relative protein levels in (H). K Clonogenic assay was performed to determine the colony formation efficiency of A2780 and SKOV3 cells. L Quantification of the number of clones in (K). (Data are mean ± SEM, ^#p > 0.05, *p < 0.05, **p < 0.01, n = 3)